Real-World Effectiveness of Zamerovimab and Mazorelvimab and Vaccine for Rabies Grade III Exposure in Nanyang
Clinical trial NCT07624461 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07624461
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-06-06
- Primary completion
- 2026-03-31
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.